Overview
TAFRO syndrome is a rare systemic inflammatory disorder characterized by thrombocytopenia, anasarca, fever, renal dysfunction, and bone marrow suppression 1.Diagnosis
Key diagnostic criteria include thrombocytopenia, anasarca, fever, renal dysfunction, and often lymphadenopathy 1.
Lymph node biopsy can confirm the diagnosis by identifying characteristic histopathological features 1.
Renal biopsy may reveal microangiopathy and glomerular changes, though specific findings can vary 1.Management
First-line treatment often includes corticosteroids to manage inflammation 1.
Adjunctive therapies may include anti-IL-6 receptor antibodies (e.g., tocilizumab) for refractory cases 1.
Anti-CD20 monoclonal antibodies (e.g., rituximab) can be considered in severe or refractory presentations 1.Special Populations
Pediatrics: Adolescent-onset TAFRO syndrome can present with severe complications like malignant nephrosclerosis-like lesions and hypertension, requiring aggressive management 1.Key Recommendations
Initiate corticosteroid therapy for managing systemic inflammation in TAFRO syndrome (Evidence: Moderate 1).
Consider anti-IL-6 receptor antibodies for patients with refractory symptoms or severe organ involvement (Evidence: Weak 1).
Evaluate the role of anti-CD20 monoclonal antibodies in refractory cases, particularly in severe presentations (Evidence: Weak 1).References
1 Nakayama Y, Mizuno H, Sawa N, Suwabe T, Yamanouchi M, Ikuma D et al.. Adolescent-onset TAFRO Syndrome with Malignant Nephrosclerosis-like Lesions. Internal medicine (Tokyo, Japan) 2023. link